Physician

Sibel Blau, M.D.

According to 2025 Medicare claims, Sibel Blau, M.D. (NPI: 1962490797) practices hematology/oncology in the Tacoma-Lakewood, WA market, with the plurality of this provider's patient population coming from Pierce, WA. This provider's primary affiliated billing organization is NORTHWEST MEDICAL SPECIALTIES PLLC (NPI: 1548261308; TIN: 911867315) and primary practice location at 98373-1659. Blau is affiliated with the CommonSpirit ACO I (ACO ID: A2164), participating under the MSSP model.

Blau's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 459 traditional Medicare patients, billed 44,553 HCPCS/CPT codes, and received $725,541 in Medicare payments. The top billing code was 82728 (Ferritin (blood protein) level). Part D data shows 1,211 prescription claims across 217 beneficiaries totaling $2,831,827 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 38 claims. Open Payments data shows 78 records totaling $1,102,754. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $1,975,521 to $725,541. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $799,983 to $2,831,827. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	586	151,080	$1,975,521
2016	708	242,845	$1,845,674
2017	973	303,136	$2,294,053
2018	1,092	222,889	$2,138,474
2019	905	194,846	$1,643,709
2020	865	161,066	$2,057,701
2021	1,395	153,420	$2,206,643
2022	772	123,436	$1,641,065
2023	605	65,496	$775,491
2024	459	44,553	$725,541

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	268	2,939	$799,983
2016	295	3,065	$1,626,950
2017	360	3,231	$1,943,112
2018	399	3,250	$2,504,349
2019	397	2,926	$3,968,618
2020	351	2,462	$4,666,730
2021	344	2,323	$4,146,094
2022	320	1,908	$4,822,286
2023	254	1,338	$3,574,918
2024	217	1,211	$2,831,827

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	14	238	$52,587
2016	N/R	199	$32,896
2017	N/R	207	$19,620
2018	12	94	$12,231
2019	N/R	17	$1,020
2020	N/R	16	$2,554
2021	N/R	84	$6,202
2022	N/R	90	$3,698
2023	N/R	62	$7,564
2024	N/R	38	$1,009

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
82728	Ferritin (blood protein) level	112	186	$13
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	126	255	$13
80053	Blood test, comprehensive group of blood chemicals	365	1,343	$10
36415	Insertion of needle into vein for collection of blood sample	346	1,343	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	343	1,360	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	57	1,505	$619,960
Revlimid	Lenalidomide	28	784	$496,827
Pomalyst	Pomalidomide	19	525	$487,547
Ibrance	Palbociclib	23	644	$348,951
Tukysa	Tucatinib	11	330	$282,882

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	20	$671
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	18	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	21	$3,730	Janssen Scientific Affairs, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	57	$1,099,024	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sibel Blau, M.D.?

Tedicare shows public-source Medicare data for Sibel Blau, M.D. (NPI 1962490797), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sibel Blau, M.D. have ACO affiliation data?

Sibel Blau, M.D. is shown with ACO affiliation data for CommonSpirit ACO I (MSSP, ACO ID A2164).

What billing organization is linked to Sibel Blau, M.D.?

Sibel Blau, M.D. is linked to NORTHWEST MEDICAL SPECIALTIES PLLC (billing NPI 1548261308) in the available physician profile data.

Does Sibel Blau, M.D. have Open Payments data?

Sibel Blau, M.D. has 78 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.